Literature DB >> 25180280

Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines.

Mary Ella M Pierpont1, Pilar L Magoulas2, Saleh Adi3, Maria Ines Kavamura4, Giovanni Neri5, Jacqueline Noonan6, Elizabeth I Pierpont7, Kent Reinker8, Amy E Roberts9, Suma Shankar10, Joseph Sullivan11, Melinda Wolford12, Brenda Conger13, Molly Santa Cruz13, Katherine A Rauen14.   

Abstract

Cardio-facio-cutaneous syndrome (CFC) is one of the RASopathies that bears many clinical features in common with the other syndromes in this group, most notably Noonan syndrome and Costello syndrome. CFC is genetically heterogeneous and caused by gene mutations in the Ras/mitogen-activated protein kinase pathway. The major features of CFC include characteristic craniofacial dysmorphology, congenital heart disease, dermatologic abnormalities, growth retardation, and intellectual disability. It is essential that this condition be differentiated from other RASopathies, as a correct diagnosis is important for appropriate medical management and determining recurrence risk. Children and adults with CFC require multidisciplinary care from specialists, and the need for comprehensive management has been apparent to families and health care professionals caring for affected individuals. To address this need, CFC International, a nonprofit family support organization that provides a forum for information, support, and facilitation of research in basic medical and social issues affecting individuals with CFC, organized a consensus conference. Experts in multiple medical specialties provided clinical management guidelines for pediatricians and other care providers. These guidelines will assist in an accurate diagnosis of individuals with CFC, provide best practice recommendations, and facilitate long-term medical care.
Copyright © 2014 by the American Academy of Pediatrics.

Entities:  

Keywords:  BRAF mutation; MEK1 mutation; MEK2 mutation; RASopathy; cardio-facio-cutaneous syndrome; management guidelines

Mesh:

Year:  2014        PMID: 25180280      PMCID: PMC4179092          DOI: 10.1542/peds.2013-3189

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  70 in total

Review 1.  Clinical manifestations of mutations in RAS and related intracellular signal transduction factors.

Authors:  Martin Zenker
Journal:  Curr Opin Pediatr       Date:  2011-08       Impact factor: 2.856

2.  The Noonan-CFC controversy.

Authors:  G Neri; M Zollino; J F Reynolds
Journal:  Am J Med Genet       Date:  1991-06-01

3.  Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes.

Authors:  Christian P Kratz; Suthee Rapisuwon; Helen Reed; Henrik Hasle; Philip S Rosenberg
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-15       Impact factor: 3.908

4.  Scoliosis and Chiari malformation Type I in children.

Authors:  Mark D Krieger; Yuri Falkinstein; Ira E Bowen; Vernon T Tolo; J Gordon McComb
Journal:  J Neurosurg Pediatr       Date:  2011-01       Impact factor: 2.375

5.  Autoimmune disease and multiple autoantibodies in 42 patients with RASopathies.

Authors:  Caio R D C Quaio; Jozélio F Carvalho; Clovis A da Silva; Cleonice Bueno; Amanda S Brasil; Alexandre C Pereira; Alexander A L Jorge; Alexsandra C Malaquias; Chong A Kim; Débora R Bertola
Journal:  Am J Med Genet A       Date:  2012-04-09       Impact factor: 2.802

6.  Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome.

Authors:  D H Siegel; J McKenzie; I J Frieden; K A Rauen
Journal:  Br J Dermatol       Date:  2011-01-28       Impact factor: 9.302

7.  Genomic duplication of PTPN11 is an uncommon cause of Noonan syndrome.

Authors:  John M Graham; Nancy Kramer; Bassem A Bejjani; Christian T Thiel; Claudio Carta; Giovanni Neri; Marco Tartaglia; Martin Zenker
Journal:  Am J Med Genet A       Date:  2009-10       Impact factor: 2.802

8.  The CFC syndrome--report of the first two cases outside the United States.

Authors:  G Neri; G Sabatino; E Bertini; M Genuardi
Journal:  Am J Med Genet       Date:  1987-08

Review 9.  The cardio-facio-cutaneous syndrome: report of a patient and review of the literature.

Authors:  A Bottani; I Hammerer; A Schinzel
Journal:  Eur J Pediatr       Date:  1991-05       Impact factor: 3.183

10.  Germline KRAS mutations cause Noonan syndrome.

Authors:  Suzanne Schubbert; Martin Zenker; Sara L Rowe; Silke Böll; Cornelia Klein; Gideon Bollag; Ineke van der Burgt; Luciana Musante; Vera Kalscheuer; Lars-Erik Wehner; Hoa Nguyen; Brian West; Kam Y J Zhang; Erik Sistermans; Anita Rauch; Charlotte M Niemeyer; Kevin Shannon; Christian P Kratz
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

View more
  39 in total

Review 1.  Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association.

Authors:  Mary Ella Pierpont; Martina Brueckner; Wendy K Chung; Vidu Garg; Ronald V Lacro; Amy L McGuire; Seema Mital; James R Priest; William T Pu; Amy Roberts; Stephanie M Ware; Bruce D Gelb; Mark W Russell
Journal:  Circulation       Date:  2018-11-20       Impact factor: 29.690

2.  In vivo severity ranking of Ras pathway mutations associated with developmental disorders.

Authors:  Granton A Jindal; Yogesh Goyal; Kei Yamaya; Alan S Futran; Iason Kountouridis; Courtney A Balgobin; Trudi Schüpbach; Rebecca D Burdine; Stanislav Y Shvartsman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-03       Impact factor: 11.205

3.  Assessing the gene-disease association of 19 genes with the RASopathies using the ClinGen gene curation framework.

Authors:  Andrew R Grant; Brandon J Cushman; Hélène Cavé; Mitchell W Dillon; Bruce D Gelb; Karen W Gripp; Jennifer A Lee; Heather Mason-Suares; Katherine A Rauen; Marco Tartaglia; Lisa M Vincent; Martin Zenker
Journal:  Hum Mutat       Date:  2018-11       Impact factor: 4.878

4.  Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients.

Authors:  Mark D Levin; Sulagna C Saitta; Karen W Gripp; Tara L Wenger; Jaya Ganesh; Jennifer M Kalish; Michael R Epstein; Rosemarie Smith; Richard J Czosek; Stephanie M Ware; Paula Goldenberg; Angela Myers; Kathryn C Chatfield; Matthew J Gillespie; Elaine H Zackai; Angela E Lin
Journal:  Am J Med Genet A       Date:  2018-07-28       Impact factor: 2.802

Review 5.  ERK signalling: a master regulator of cell behaviour, life and fate.

Authors:  Hugo Lavoie; Jessica Gagnon; Marc Therrien
Journal:  Nat Rev Mol Cell Biol       Date:  2020-06-23       Impact factor: 94.444

6.  Comparison of hair manifestations in cardio-facio-cutaneous and Costello syndromes highlights the influence of the RAS pathway on hair growth.

Authors:  J Urban; L Qi; H Zhao; I Rybak; K A Rauen; M Kiuru
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-01-02       Impact factor: 6.166

Review 7.  JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities.

Authors:  Katherine R Calvo; Susan Price; Raul C Braylan; Joao Bosco Oliveira; Michael Lenardo; Thomas A Fleisher; V Koneti Rao
Journal:  Blood       Date:  2015-02-17       Impact factor: 22.113

8.  A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles Noonan syndrome with loose anagen hair.

Authors:  Karen W Gripp; Kimberly A Aldinger; James T Bennett; Laura Baker; Jessica Tusi; Nina Powell-Hamilton; Deborah Stabley; Katia Sol-Church; Andrew E Timms; William B Dobyns
Journal:  Am J Med Genet A       Date:  2016-06-05       Impact factor: 2.802

9.  Selective Translation of Cell Fate Regulators Mediates Tolerance to Broad Oncogenic Stress.

Authors:  Elise Y Cai; Megan N Kufeld; Samantha Schuster; Sonali Arora; Madeline Larkin; Alexandre A Germanos; Andrew C Hsieh; Slobodan Beronja
Journal:  Cell Stem Cell       Date:  2020-06-08       Impact factor: 24.633

Review 10.  Recent advances in RASopathies.

Authors:  Yoko Aoki; Tetsuya Niihori; Shin-ichi Inoue; Yoichi Matsubara
Journal:  J Hum Genet       Date:  2015-10-08       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.